Kailera Therapeutics, Inc.
KLRANext catalyst
Ribupatide
Obesity
Get an email about KLRA's next catalysts
Track Kailera Therapeutics (KLRA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (earnings, Phase 2 readout).See the timeline
3 upcoming, 1 past
KLRA Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-1.55 | FQ end Sep/2026 | Call: tbd
Ribupatide Phase 2 Est. Readout
Estimated primary completion for Ribupatide trial (NCT07458269) in Obesity. Topline data typically follows completion by weeks to months.
SourceKAI-7535 Phase 2 Est. Readout
Primary completion for KAI-7535 trial (NCT07497880) in Obesity
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ribupatide | Phase 3 | Obesity | - | - |
KAI-9531 | Phase 3 | Obesity With Diabetes | - | - |
KAI-7535 | Phase 2 | Obesity | - | - |
Frequently asked questions
What is in Kailera Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Kailera Therapeutics, Inc.'s (KLRA) pipeline across Phase 3, Phase 2. Its lead program is Ribupatide (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Kailera Therapeutics, Inc.'s next FDA catalyst?→
Kailera Therapeutics, Inc.'s (KLRA) next tracked catalyst is a Phase 2 readout expected May 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track KLRA biotech catalysts?→
Add KLRA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Kailera Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.